期刊文献+

N-乙酰化转移酶2基因多态性与抗结核药物所致肝损伤的相关性 被引量:3

The relationship between polymorphisms of N-acetyltransferase 2 genes and anti-tuberculosis drug induced hepatic-injury
原文传递
导出
摘要 目的探讨N-乙酰化转移酶2(NAT2)基因多态性与抗结核药致肝损伤(ADIH)的相关性。方法以抗结核治疗3个月内出现肝损伤的106例结核患者为病例组,未出现肝损伤的106例结核患者为配对对照。采用1:1匹配的病例对照研究和聚合酶链反应限制性片段长度多态性分析(PCRRFI,P)技术,检测106对结核患者的NAT2基因481C/T、590G/A、857G/A位点多态性情况,并对主要环境影响因素和基因型进行单因素和多因素条件Logistic回归分析。结果病例组NAT2基因的481C/T、590G/A、8576/A位点的T、A、A等位基因频率分别为7.5%、28.8%、17.9%,对照组分别为6.6%、18.9%、17.5%。病例组NAT2慢速乙酰化型的频率明显高于对照组,粗OR值为2.250(95%CI为1.140~4.441)。对文化程度、职业、体质指数(BMI)、吸烟、饮酒和结核类型6个可疑危险因素进行了单因素分析,仅低BMI和饮酒为ADIH发生的危险因素。在多因素分析中调整BMI、饮酒两个因素后,NAT2乙酰化程度仍与ADIH的发生显著相关,调整OR值为2.246(95%CI为1.086~4.644)。结论NAT2基因慢速乙酰化型可能与ADIH的发生有关。 Objective To investigate the relationship between polymorphisms of N acetyltransferase 2 (NAT2) genes and anti tuberculosis drug induced hepatic-injury (ADIH). Methods A 1 : 1 matched case-control study was conducted. One hundred and six cases fulfilling the criteria of ADIH were selected as ADIH group from the patients who received anti-tuberculosis therapy, whereas those patients without any hepatic injury related clinical symptoms during three months of follow-up period were selected as control. The genetic polymorphisms of the loci, NAT2- 481C/T, NAT2-590G/A and NAT2 857G/A, were determined by polymerase chain reaction and restriction fragment length polymorphism technique (PCR RFLP) in patients who received anti tuberculosis therapy. The major environmental factors and genotypes were analyzed by univariate and rnuhivariate conditional Logistic analyses. Results The T, A, A allele frequencies of NAT2-481C/T, NAT2-590G/A and NAT2-857G/A were 7.5 ~//00, 28.8~ and 17.9~ respectively in ADIH group, and 6.6~/oo ,18.9~ and 17. 5o//oo, respectively in the control group. Univariate analysis demonstrated that the frequency of NAT2 slow acetylation genotype in ADIH group was significantly higher than that in control group with a crudeOR (95%CI) of 2. 250 (1.140-4.441). Among 6 potential risk factors, i.e. education level, occupation, body mass index (BMI), smoking, drinking and tile type of tuberculosis, the low BMI and drinking were two risk factors for ADIH. In multivariate analysis, ADIH remained associated with acetylation gcnotype after adjusting for BMI and drinking status. The adjusted OR(95%CI)was 2.246(1. 086-4. 644). Conclusion NAT2 slow aeetylation genotype may be associated with the occurrence of ADIH.
出处 《中华传染病杂志》 CAS CSCD 北大核心 2010年第2期99-102,共4页 Chinese Journal of Infectious Diseases
基金 唐山市重点实验室资助项目(08150201A-1-8)
关键词 乙酰基转移酶类 多态现象 遗传 抗结核药 肝炎 中毒性 病例对照研究 toxic Case control genetic Antitubercular agents Hepatitis
  • 相关文献

参考文献7

  • 1刘萱,贾继东.药物性肝损害的发生机制及诊断发展[J].临床肝胆病杂志,2006,22(2):150-151. 被引量:38
  • 2Lemos MC, Cabrita FJ, Silva HA, et al. Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias. Carcinogenesis, 1999,20: 1225-1229.
  • 3Fretland A J, Leff MA, Doll MA, et al. Functional characterization of human N-acetyltransferase- 2 (NAT2) single nucleotide polymorphisms. Pharmacogenetics, 2001, 11,207 -215.
  • 4谭守勇,林兆原,关玉华,李嫣红,潘爱华,黎燕琼,粱敏青.蛋白质营养不良对抗结核药物肝损害的影响[J].中国防痨杂志,2006,28(2):83-86. 被引量:44
  • 5Chen B, Zhang WX, Cai WM. The influence of various genotypes on the metabolic activity of NAT2 in a Chinese population. Eur J Clin Pharmacol, 2006,62:355-359.
  • 6Ohno M, Yamaguchi I, Yamamoto I, et al. Slow N acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin induced hepatotoxicity, lnt J Tuberc Lung Dis, 2000,4:256- 261.
  • 7Huang YS, Chern HD, Su WJ, et al, Polymorphism of the N acetyhransferase 2 gene as a susceptibility risk factor forantituberculosis drug-induced hepatitis. Hepatology, 2002, 35:883-889.

二级参考文献22

  • 1侯恕.呼吸疾病的营养支持(现代呼吸系疾病系统讲座第十讲)[J].中华结核和呼吸杂志,1996,19(3):133-135. 被引量:49
  • 2中华医学会结核病学分会.中国结核病分类法[J].中华结核和呼吸杂志,1998,21(12):716-716.
  • 3Sharms SK,Balamurugan A,Saha PK.et al.Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment[J].Am J Respir Crit Care Med,2002,166(7):916-919.
  • 4Teleman MD,Chee CBE,Earnest A.et al.Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore[J].Int Tuberc Lung Dis,2002,6(8):699-705.
  • 5American Thoracic Society/Centers For Disease Control and Prevention (ATS/CDC).Executive Committee,Update:Fatal and Severe Liver Injuries Associated With Rifampin and Pyrazinamide for Latent Tuberculosis Infection,and Revisions in American Thoracic Society/CDC Recommendations-United States,2001[J].Am J Respir Crit Care Med,2001,164(7):1319-1320.
  • 6Nolan CM,Goldberg SV,Buskin SE.Hepatotoxicity associated with isoniazid prevention therapy[J].JAMA,1999,281:1014-1018.
  • 7Ungo JR,Jones DA,shkin D.et al.Antituberculosis drug-induced hepatotoxicity the role of hepatitis C virus and the human immunodeficiency virus[J].Am J Respir Crit Care Med,1998,157(7):1871-1876.
  • 8Wang WM,Wu PC,Yuen MF,et al.Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection[J].Hepatology,2000,31:201-206.
  • 9Maria VA,Victorino RM.Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis[J].Hepatology,1997,26 (3):664-669.
  • 10Aithal GP,Rawlins MD,Day CP.Clinical diagnostic scale:a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions[J].J Hepatol,2000,33(6):949-952.

共引文献80

同被引文献24

  • 1覃文杰,周宏灏.CYP2B6基因多态性及其功能意义的研究进展[J].中国临床药理学与治疗学,2008,13(12):1434-1440. 被引量:7
  • 2欧江荣,谭兰,孙妍萍.丙戊酸药物浓度与CYP2B6基因多态性的相关性研究[J].中国临床神经科学,2007,15(4):378-381. 被引量:7
  • 3Lin-yong XU,Yi-jing HE,Wei ZHANG,Sheng Deng,Qing LI,Wei-xia ZHANG,Zhao-qian LIU,Dan WANG,Yuan-fei HUANG,Hong-hao ZHOU,Zhen-qiu SUN.Organic anion transporting polypeptide-1B1 haplotypes in Chinese patients[J].Acta Pharmacologica Sinica,2007,28(10):1693-1697. 被引量:18
  • 4Norihide Higuchi,Naoko Tahara,Katsunori Yanagihara,Kiyoyasu Fukushima,Naofumi Suyama,Yuichi Inoue,Yoshitsugu Miyazaki,Tsutomu Kobayashi,Koh-ichiro Yoshiura Norio Niikawa, Chun-Yang Wen, Hajime Isomoto,Saburou Shikuwa, Katsuhisa Omagari, Yohei Mizuta, Shigeru Kohno, Kazuhiro Tsukamoto,Norio Niikawa,Chun-Yang Wen,Hajime Isomoto,Saburou Shikuwa,Katsuhisa Omagari,Yohei Mizuta,Shigeru Kohno,Kazuhiro Tsukamoto.NAT2*6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis[J].World Journal of Gastroenterology,2007,13(45):6003-6008. 被引量:21
  • 5Rendic S. Summary of information on human CYP enzymes: humanP450 metabolism data [J]. Drug Metab Rev, 2002,34: 83-448.
  • 6Guengerich FP. Human cytochrome P450 enzymes [A]. Ortiz de Montel-lano PR. Cytochrome P450,New York: Plenum, 1995:473-535.
  • 7Lang T, Klein K, Fischer J, et al. Extensive genetic polymorphism inthe human CYP2B6 gene with impact on expression and function in hu-man liver [J]. Pharmacogenetics, 2001, 11: 399-415.
  • 8Huang Y S, Chem H D, Su W J, et al. Polymorphism of the N-acetyl-transferase 2 gene as a susceptibility risk factor for antituberculosisdrug-induced hepatitis [J]. Hepatology, 2002, 35(4): 883-839.
  • 9Wen X, Wang J S, Neuvonen P J,et al. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 is oforms in human liver microsomes [J]. Eur J Clin Pharmacol, 2002, 57(11):799-804.
  • 10Vuilleumie N, Rossier M F, Chiappe A, et al. CYP2E1 genotype andisoniazid-induced hepatotoxicity in patients treated for latent tubercu-losis [J]. Eur J Clin Pharmacol, 2006,62(6): 423-429.

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部